Synthetic strategies to lower affinity for CYP2D6

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Enzymology

Background:

• The cytochrome P450 2D6 (CYP2D6) enzyme plays a crucial role in drug metabolism.
• Imipramine is a known substrate and inhibitor of CYP2D6, necessitating strategies to manage this interaction.
• Understanding CYP2D6 active site models is key to designing drugs with reduced enzyme affinity.

Purpose of the Study:

• To investigate synthetic strategies for modifying imipramine to decrease its interaction with the CYP2D6 enzyme.
• To evaluate the impact of structural alterations on imipramine's inhibitory potency against CYP2D6.
• To correlate molecular changes with the known characteristics of the CYP2D6 active site.

Main Methods:

• Inhibition assays using bufuralol 1'-hydroxylation as a marker for CYP2D6 activity.
• Synthesis of imipramine analogs with modified basicity and alkyl chain lengths.
• Evaluation of inhibitory effects of synthesized compounds on CYP2D6 activity in a cell line.

Main Results:

• Imipramine inhibited bufuralol 1'-hydroxylation with an IC50 of 2.4 microM.
• Removal of the basic center (imipramine N-oxide) abolished inhibitory activity.
• Modifications to alkyl chain length and introduction of a carbonyl group reduced inhibitory potency.
• Structural changes distal to the basic center attenuated imipramine's affinity for CYP2D6.

Conclusions:

• Synthetic modifications, particularly those altering structural features distal to the basic center, can effectively attenuate imipramine's affinity for CYP2D6.
• While reducing enzyme interaction is possible, potential impacts on pharmacological efficacy must be considered.
• These findings align with established models of the CYP2D6 active site and substrate interactions.